Revisiting the Potential Role of a Restricted CB1 Inhibitor
In this update of Skye’s Anatomy of Progress video series, we highlight Skye’s positioning and progress in obesity therapeutic drug development, noting the differentiation of its allosteric modulating antibody that takes into consideration fat metabolism, safety and long-term care.
Related Documents:
Anatomy of Progress-Review of Landscape: Slides